MONTREAL

Thryv Therapeutics Inc. Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Thursday, April 4, 2024
Atrial fibrillation, Medicine, LQTS, Metro Toronto Convention Centre, Conference, Heart failure, Biotechnology, Therapy

Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Key Points: 
  • Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Pharmascience Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Wednesday, April 3, 2024
Metro Toronto Convention Centre, Conference, Interest

Montreal, Quebec--(Newsfile Corp. - April 3, 2024) - Pharmascience Inc., the largest Canadian-owned pharmaceutical company and a leader in the Canadian generic market, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Key Points: 
  • Montreal, Quebec--(Newsfile Corp. - April 3, 2024) - Pharmascience Inc., the largest Canadian-owned pharmaceutical company and a leader in the Canadian generic market, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.
  • Martin Arès, CEO will be speaking at 9:30am ET on April 17th.
  • Members of the Pharmascience Inc. management team will also be taking meetings throughout the day.
  • To register for the 2024 Bloom Burton & Co. Healthcare Investor Conference, please follow this link .

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Metro Toronto Convention Centre, GUD, TSX, Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.

Key Points: 
  • MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.
  • ET at the Metro Toronto Convention Centre in Toronto.
  • A copy of the presentation will be available at www.knighttx.com .

Gildan Activewear Announces Investor Update on April 15, 2024

Retrieved on: 
Monday, April 8, 2024
GIL, TSX

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today announces that its President and CEO, Vince Tyra, will provide an Investor Update in an upcoming webcast event on April 15, 2024, marking his first 90 days at Gildan.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today announces that its President and CEO, Vince Tyra, will provide an Investor Update in an upcoming webcast event on April 15, 2024, marking his first 90 days at Gildan.
  • Vince was appointed President and CEO on December 11, 2023, and assumed his new position on January 15, 2024.
  • The event will take place on April 15, 2024, at 4:45 PM ET.
  • A live audio webcast of the conference call and presentation, as well as a replay, will be available at the following link: Gildan Investor Update.

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

Peak and CSL Join Forces in Europe as Peak CSL Group

Retrieved on: 
Monday, April 8, 2024
CSL, Canada Steamship Lines, Farm, Growth, Steel, Partnership, Acquisition, Engineering, Renewable energy

BERGEN, Norway and MONTREAL, Canada, April 08, 2024 (GLOBE NEWSWIRE) -- Peak Group (“Peak”) and The CSL Group (“CSL”) are pleased to announce the launch of their new partnership, Peak CSL Group, following CSL’s acquisition of 50% of Peak.

Key Points: 
  • BERGEN, Norway and MONTREAL, Canada, April 08, 2024 (GLOBE NEWSWIRE) -- Peak Group (“Peak”) and The CSL Group (“CSL”) are pleased to announce the launch of their new partnership, Peak CSL Group, following CSL’s acquisition of 50% of Peak.
  • Under the Peak CSL Group banner, the company is positioned to provide an expanded suite of services, particularly catering to the fast-growing offshore renewable energy sector.
  • A cornerstone of the Peak CSL Group philosophy is a proactive stance in driving forward decarbonisation in the shipping industry.
  • “Through the Peak CSL Group, we create a strong alliance, grounded in our strategy for the next coming years.

Osisko Announces Q1 2024 Geo Deliveries and Select Asset Updates

Retrieved on: 
Monday, April 8, 2024
Odyssey, Mining, Copper, Australian Securities Exchange, Osisko Gold Royalties, Silver, SSRP, GEOS, SAG, Gold, Senate, Annual report, Corporation, ASX, Acquisition, Mineral, Refused, CSA, Abitibi, Agnico Eagle, Ventilation, NSR, Resource

In addition, Osisko is excited to provide some select asset updates.

Key Points: 
  • In addition, Osisko is excited to provide some select asset updates.
  • Osisko earned 22,259 attributable gold equivalent ounces1 (“GEOs”) in the first quarter of 2024.
  • Osisko owns a 2% NSR royalty on the Ermitaño project and the Cumobabi property, including the Luna and Soledad Zones.
  • Osisko provides notice of the first quarter 2024 results and conference and webcast call details.

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Retrieved on: 
Monday, April 8, 2024
FACC, American College, Atrial flutter, Patient, Journal, History, Doctor of Philosophy, MD, Ventricular fibrillation, ACC, Pharmaceutical industry

“The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.

Key Points: 
  • “The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.
  • CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable, and at-the-ready option in the acute treatment of PSVT.
  • NODE-303 (ClinicalTrials.gov ID NCT04072835 ) evaluated self-administered etripamil (70 mg, nasal spray) in an outpatient setting for up to multiple episodes of PSVT, without prior test dosing.
  • Both the presentation and publication will be available on the Milestone Pharmaceuticals corporate website at the conclusion of the ACC presentation.

Yellow Pages launches nationwide cover art competition

Retrieved on: 
Monday, April 8, 2024
Biography, Celebrate, Painting, Social media, Competition law, Ice cream, Senior, Yellow pages, Marketing, Creativity, Customer service, Directory

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Yellow Pages Digital & Media Solutions Limited (“Yellow Pages”), a leading Canadian digital media and marketing company, is thrilled to announce a nationwide art competition “Our Cover, Your Canvas”.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Yellow Pages Digital & Media Solutions Limited (“Yellow Pages”), a leading Canadian digital media and marketing company, is thrilled to announce a nationwide art competition “Our Cover, Your Canvas”.
  • Competition Details: Participants are invited to submit their artwork through a dedicated competition website: www.ypsolutions.ca/submissions or www.ypsolutions.ca/soumissions .
  • Prize: The confirmed winners will have their artwork featured on the front cover of selected Yellow Pages print directories across Canada starting in 2025.
  • “At Yellow Pages, we connect people and businesses in neighbourhoods across Canada through our print, digital properties and services.

Global Net Lease Announces $237 Million CMBS Re-Financing

Retrieved on: 
Monday, April 8, 2024
Risk, Loan, Bank, Acquisition, Bank of Montreal, KeyBank, CMBS, GNL, Barclays

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”) announced today that the Company completed a $237 million commercial mortgage-backed security loan (the “Loan”) secured by 20 U.S. industrial properties previously secured under the Company’s corporate credit facility.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”) announced today that the Company completed a $237 million commercial mortgage-backed security loan (the “Loan”) secured by 20 U.S. industrial properties previously secured under the Company’s corporate credit facility.
  • The lead lender for the Loan is Bank of Montreal and co-lenders are Barclays, KeyBank and Société Générale.
  • We are pleased with the strategic execution of this CMBS financing as the fixed rate debt lowers GNL’s existing cost of capital and improves our weighted average debt maturity.
  • Global Net Lease, Inc. (NYSE: GNL) is a publicly traded internally managed real estate investment trust that focuses on acquiring and managing a global portfolio of income producing net lease assets across the U.S., and Western and Northern Europe.